AN2 Therapeutics

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.